Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
NYSE:NVO
Holding NVO?
Track your performance easily
NVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$81.50 - $148.15
Previous CloseN/A
Volume3.65M
Average Volume (3M)5.74M
Market Cap
$379.76B
Enterprise Value$528.43B
Total Cash (Recent Filing)$20.70B
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)27.7
Beta0.75
Next Earnings
Feb 05, 2025EPS Estimate
0.86Last Dividend Ex-Date
Aug 16, 2024Dividend Yield1.23%
Share Statistics
EPS (TTM)3.09
Shares Outstanding3,390,128,000
10 Day Avg. Volume6,517,654
30 Day Avg. Volume5,735,915
Standard Deviation0.07
R-Squared0.11
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.50
Price to Cash Flow (P/CF)69.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue2.48
Enterprise Value/Gross Profit2.69
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$112.25Price Target Upside31.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Novo Nordisk News
Bulls Say, Bears Say
Bulls Say
Growth PotentialNVO is well positioned in the growing diabetes and obesity market.
Innovative ProductsNext generation assets like CagriSema improve upon the profiles of currently available incretins.
Strategic AcquisitionNovo Holdings is set to win EU antitrust approval for their proposed acquisition of Catalent, which is positive for Novo shares.
Bears Say
Efficacy ConcernsCagriSema results likely underperform investor expectations reporting efficacy-estimand weight loss of 22.7% and treatment-estimand weight loss of 20.4%.
Strategic UncertaintyThe strategy surrounding an oral weight loss agent is in flux.
Supply IssuesSupply constraints are expected to continue into 2025.
---
Ownership Overview
―
Insiders
1.60% Mutual Funds
0.01% Other Institutional Investors
98.29% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $81.50 and its highest was $148.15 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $379.76B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Feb 05, 2025 which is in 27 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Nov 06, 2024. The company reported $0.881 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.001.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.374 which represents an annual dividend yield of 1.23%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.86.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.881 in its last earnings report, beating expectations of $0.88. Following the earnings report the stock price went down -4.331%.
Which hedge fund is a major shareholder of Novo Nordisk?
Among the largest hedge funds holding Novo Nordisk’s share is Fisher Asset Management LLC. It holds Novo Nordisk’s shares valued at 2B.
---
Novo Nordisk Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$112.25 (31.07% Upside)
$112.25 (31.07% Upside)
Blogger Sentiment
Bullish
NVO Sentiment 82%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 54.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.88%
12-Months-Change
Fundamentals
Return on Equity
78.59%
Trailing 12-Months
Asset Growth
39.65%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk is a global healthcare company headquartered in Denmark, specializing in the development, production, and marketing of pharmaceutical products. The company operates in two main sectors: Diabetes and Obesity care, and Biopharmaceuticals. Its core products include insulin, GLP-1 and other diabetes-related medications, as well as treatments for obesity, hemophilia, and growth hormone deficiencies.
---
NVO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong financial performance and strategic growth in key areas such as GLP-1 treatments and obesity care, supported by significant R&D achievements. However, challenges remain with increased carbon emissions, supply constraints, and issues in the rare diseases segment. Despite these challenges, the positive developments in sales, profit, and R&D outcomes suggest more highlights than lowlights.Read More>---
NVO Stock 12 Month Forecast
Average Price Target
$112.25
▲(31.07% Upside)
Technical Analysis
Best Analysts Covering NVO
1 Year
1 Year Success Rate
8/22 ratings generated profit
1 Year Average Return
+0.70%
reiterated a buy rating 2 months ago
Copying Sachin Jain's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of +0.70% per trade.
---